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Abstract
Individual case safety reports (ICSRs) are a cornerstone in drug safety surveillance. The
knowledge on using these data specifically for children is limited. We studied characteristics
of pediatric ICSRs reported to the US Food and Drug Administration (FDA) Adverse Event
Reporting System (FAERS). Public available ICSRs reported in children (0–18 years) to
FAERS were downloaded from the FDA-website for the period Jan 2004-Dec 2011. Char-
acteristics of these ICSRs, including the reported drugs and events, were described and
stratified by age-groups. We included 106,122 pediatric ICSRs (55% boys and 58% from
United States) with a median of 1 drug [range 1–3] and 1 event [1–2] per ICSR. Mean age
was 9.1 years. 90% was submitted through expedited (15-days) (65%) or periodic reporting
(25%) and 10% by non-manufacturers. The proportion and type of pediatric ICSRs reported
were relatively stable over time. Most commonly reported drug classes by decreasing fre-
quency were ‘nervous system drugs’ (58%), ‘antineoplastics’ (32%) and ‘anti-infectives’
(25%). Most commonly reported system organ classes were ‘general’ (13%), ‘nervous sys-
tem’ (12%) and ‘psychiatric’ (11%) disorders. Duration of use could be calculated for 19.7%
of the reported drugs, of which 14.5% concerned drugs being used long-term (>6 months).
Knowledge on the distribution of the drug classes and events within FAERS is a key first
step in developing pediatric specific methods for drug safety surveillance. Because of sev-
eral differences in terms of drugs and events among age-categories, drug safety signal
detection analysis in children needs to be stratified by each age group.
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Introduction
The limited knowledge about the effects of drugs in children has boosted initiatives by the
World Health Organisation (WHO) and triggered new legislation in recent years [1, 2]. The
Global Research in Paediatrics Network of Excellence (GRiP) is an EU-funded consortium,
which aims to implement an infrastructure facilitating the development and safe use of medi-
cines in children. This entails the development of a comprehensive educational programme
and integrated use of existing research capacity, whilst reducing the fragmentation and dupli-
cation of efforts [3, 4].
Post-marketing drug safety surveillance using spontaneous reporting systems is essential in
studying drug safety [5]. An important part of the GRiP project is evaluating current and devel-
oping new methodology for post-marketing drug safety studies specifically for the pediatric
population. Typical large spontaneous reporting systems include VigiBase of the WHO Upp-
sala Monitoring Center (WHO-UMC), the Adverse Event Reporting System (AERS), main-
tained by United States (US) Food and Drug Administration (FDA-AERS, FAERS), the
Vaccine Adverse Effect Reporting System (VAERS), maintained by FDA and CDC (Centers
for Disease Control and Prevention), and EudraVigilance of the European Medicines Agency
(EMA) [6–9].
While these spontaneous reporting databases were predominantly used by regulatory
authorities to monitor drug safety and to perform safety signal detection, these data are
increasingly available for research purposes. The FDA databases offer publicly downloadable
datasets [10, 11], while the EMA published their access policy for EudraVigilance in 2011 [12],
and WHO-UMC is preparing summary VigiBase data to be made accessible via their website
[13]. Understanding the structure and scope of these datasets and their respective strengths
and limitations is essential for their correct use and interpretation and a first and important
step for evaluating current and developing new methodology. In 2011 an overview of pediatric
ICSRs reported to WHO-UMC was published [14]. Published descriptions on the pediatric
reports within AERS include the number of reports, their outcome, and the most frequently
reported drugs [15–17]. However, studies rarely reported on the reported adverse events within
FAERS.
In the current study we aimed to describe the pediatric ICSRs as reported within FAERS.
Specific attention was given to describing adverse events occurring within age-categories and
after long-term drug use or with delayed onset after cessation of treatment.
Methods
Data source
FAERS is a database that contains information on adverse event and medication error reports
submitted to FDA. It is a passive surveillance system that relies on voluntary reporting by
healthcare professionals and consumers, as well as required reporting by pharmaceutical man-
ufacturers. FAERS includes spontaneous reports from US sources; serious and unlabelled spon-
taneous reports from non-US sources; and serious, unlabelled, and attributable post-marketing
clinical trial reports from all sources [10].
FAERS data is publicly available and files containing the raw data of individual case safety
reports (ICSRs) as contained within the database are available [10]. The information include:
patient demographic and administrative information; drug/biologic information; preferred
terms of MedDRA (Medical Dictionary for Regulatory Activities) of the events; patient out-
comes for the event; report sources for the event; therapy start dates and end dates; and indica-
tions of use (diagnosis) for the reported drugs.
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Data preparation
We extracted all ICSRs for the period January 2004 till December 2011 and included all ICSRs
on children, aged 0 to<18 years. We excluded the following reports from the analyses: adults
reports (18 years); reports with missing age or event; duplicate reports (e.g. in a follow-up
report, were only included once). All reported events are coded in preferred terms of MedDRA.
To facilitate high level descriptive we recoded the reported terms to a single System Organ
Classes (SOCs) of MedDRA. The reported drugs are described either as a valid trade name or
as unstructured narrative. As far as possible the reported drug names were recoded to Anatom-
ical Therapeutic Chemical (ATC) drug classes using drug dictionaries [18–21]. This recoding
was possible for>90% of the reported drugs reported in the selected ICSRs. The entries for
which recoding was not possible included reports without a specified drug name, spelling
errors. For the analyses on type of reported drugs and unique combination drug/event, only
those records with a known ATC-code were included.
Data analysis
Each of the included ICSRs was classified by the age at time of the event, sex, number of drugs
and number of events. Results were stratified by age-categories in which age at onset was strati-
fied based on the ICH (International Conference On Harmonisation) age-groups: neonates
(27 days), infants (28 days-23 months), children (2-11 years), and adolescents (12-17
years) [22].
The role of the reported drugs, being either primary suspect, secondary suspect, concomi-
tant or interacting was provided [23]. The most frequently reported drugs and events were
described. In addition, the reported events were stratified with respect to the outcome of the
event. The outcome was registered in terms of the seriousness criteria: death, life-threatening,
hospitalization (initial or prolonged), disability, congenital anomaly, requiring intervention to
prevent permanent impairment or damage or other. Using the primary suspect and secondary
suspect drugs only, the most frequent reported drug-event combinations were described.
For those drugs for which the starting date of the drug and the date of the event were
known, the time to event was calculated. An event occurred after long-term use if it occurred at
least 6 months after starting of therapy [24]. We also studied delayed events. For those records
with a known stopping date of therapy and date of the event, the type of reported events occur-
ring>3 months after drug cessation were compared with the type of events occurring during
drug use.
Characteristics of the ICSRs were compared using chi-square to compare proportions and
either students-t test, if variable was normally distributed or Mann-Whitney tests if the variable
was not normally distributed to compare means. A p-value<0.05 was considered to be statisti-
cal significant.
Results
The overall publicly available dataset of FAERS included 3,691,417 ICSRs. Among them,
3,585,295 ICSRs were excluded, 2,311,727 of which concerned adults, 1,234,941 with age and/
or event missing, and 38,627 duplicates. Accordingly, 106,122 (2.9%) ICSRs occurred in chil-
dren<18 years and were included in the analyses. The mean age of the children in these
reports was 9.1 years. 10.5% of the ICSRs were on children up to one year of age, after which
this decreased to 3.6% at 4 to 5 years of age and gradually increased again to 8.9% at 17–18
years of age (Fig 1). The majority of the ICSRs (54.5%) were reported for boys; reports for boys
exceeded those for girls up to the age of 11 years (54.1–59.9%) and this reversed from the age
of 12 years onwards (47.7%), the mean age in the female reports was higher than for male
Description of Pediatric Adverse Events Reported to FDA-AERS
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reports (p<0.001). The ICSRs comprised a total of 236,491 drug records (median 1 drug/
ICSR). The ICSRs comprised a total 397,220 event records (median 1 event/ICSR) (Table 1).
The outcome in terms of seriousness criteria was: 33% hospitalization (initial or prolonged);
12% death; 3% life-threatening; 3% disability; 2% congenital anomaly; 1% required interven-
tion to prevent permanent impairment or damage; 31% other and was missing in 15% (data
not shown).
The number of ICSRs reported by calendar year is increasing, with a small dip in 2010
(Fig 2).
Of the included ICSRs, 10.0% (N = 10,576) concerned direct reporting, defined as ICSRs
being voluntary submitted by “non-manufacturers”. The majority of the ICSRs were submitted
by manufacturers; 64.9% (N = 68,886) were expedited reports and 25.1% (N = 26,660) were
periodic reports. The reporter was a physician in 32.0% of the ICSRs, a consumer in 24.9% and
another health professional in 20.0%. The majority of the reports originated from the US
(58%), followed by Japan (7.0%) and the United Kingdom (6.6%) (Table 2).
Among the included ICSRs, 35% of reported drugs were indicated as primary suspected,
21% as secondary suspected and the remaining drugs as concomitant or interacting (44%).
‘Nervous system drugs’, ‘antineoplastics’ and ‘anti-infective agents’ were the most frequently
reported drug class in all age-categories (Fig 3). Specifically, among ‘nervous system drugs’,
mainly ‘antiepileptic drugs’ and ‘analgesics’ were reported in the youngest children and drugs to
treat ADHD in the older children (Table 3). ‘Anti-infectives’ were an important group of the
reported drugs for the youngest children, covering 22% of the reported drugs in children<27
days of age (‘antiretroviral drugs’ and ‘antibiotics’) and 20% of the drugs in children aged 28
Fig 1. Number of reported ICSRs by age.Within the bars the proportion of ICSRs within this age-stratum of
the total reported pediatric ICSRs is given.
doi:10.1371/journal.pone.0130399.g001
Table 1. Distribution of pediatric ICSRs (N = 106,122) within FAERS according to age-category.
Total  27 days 28 days-23 months 2–11 years 12–17years
N = 106,122 (%) N = 4,717 (4.4%) N = 16,096 (15.2%) N = 47,248 (44.5%) N = 38,061 (35.9%)
Males 54,768 (54.5%) 2,114 (54.1%) 7,921 (55.3%) 27,075 (59.9%) 17,658 (47.7%)
Mean age (95%CI) 9.1 (9.0–9.1)
Reported drugs 236,491 12,180 (5.2%) 34,575 (14.6%) 103,988 (44.0%) 85,748 (36.3%)
Drugs/ICSR [median (IQR)] 1 (1–3) 1 (1–3) 1 (1–3) 1 (1–3) 1 (1–3)
Reported events 397,220 21,265 (5.4%) 59,306 (14.9%) 173,395 (43.7%) 143,254 (36.1%)
Events/ICSR [median (IQR)] 1 (1–1) 1 (1–2) 1 (1–2) 1 (1–1) 1 (1–1)
doi:10.1371/journal.pone.0130399.t001
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days to 23 months (‘specific immunoglobulins’ and ‘antibiotics’). In the older children the ‘anti-
infectives’ covered a smaller proportion of the drugs and ‘antineoplastic drugs’ became of more
importance; 17% in children aged 2 to 11 years and 16% in children aged 12 to 17 years.
Fig 2. Number of reported ICSRs over time. The number of included pediatric ICSRs is plotted on the left y-
axis. The total number of ICSRs within the database is plotted on the right y-axis. Within the bars the
proportion of pediatric ICSRs of the total reported ICSRs is given.
doi:10.1371/journal.pone.0130399.g002
Table 2. Main characteristics of pediatric ICSRs (N = 106,122) within FAERS.
Type of report N of ICSRs (%)
Direct reporting 10,576 (10.0%)
Expedited reports (“15 day reports”) 68,886 (64.9%)
Periodic reports 26,660 (25.1%)
Reporter
Physician 33,990 (32.0)
Consumer/non-health professional 26,378 (24.9)
Other health professional 21,193 (20.0)
Pharmacist 6,159 (5.8)
Lawyer 1,301 (1.2)
Unspeciﬁed 17,101 (16.1)
Initial source
Foreign 10,290 (9.7%)
Study 164 (0.2%)
Literature 882 (0.8%)
Consumer 10,123 (9.5%)
Health Professional 11,196 (10.6%)
User Facility 14 (0.0%)
Company representative 3,964 (3.7%)
Distributor 229 (0.2%)
Other 554 (0.5%)
Unknown 68,706 (64.7%)
Country
United States 50,625 (47.7%)
Japan 6,119 (5.8%)
United Kingdom 5,722 (5.4%)
France 4,656 (4.4%)
Germany 2,758 (2.6%)
Unknown 18,827 (17.7%)
doi:10.1371/journal.pone.0130399.t002
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In the Fig 4 the reported events are stratified by their System Organ Classes (SOCs) and by
age-categories. The ten most frequently reported events are presented in the Table 4. The
reported events were most frequently situated in the SOCs ‘general disorders and administra-
tion site conditions’ (13%) (e.g. ‘vomiting’ and ‘pyrexia’), ‘nervous system disorders’ (12%) (e.g.
‘convulsion’ and ‘headache’), and ‘psychiatric disorders’ (11%) (e.g.‘abnormal behaviour’ and
‘aggression’). In the youngest group of children ‘pregnancy, puerperium and perinatal condi-
tions’ (16%) and ‘congenital, familial and genetic disorders’ (11%) covered a large part of the
reported events (e.g. ‘drug exposure during pregnancy’, ‘premature baby’ and ‘maternal drugs
affecting foetus’). The proportion of ‘psychiatric disorders’ increased with age from 5% at27
Fig 3. Proportions of reported drugs by anatomical main group.Distribution of the number of reported
drugs over anatomical main group (1st level ATC),stratified by age-categories. The reported ATC classes are
presented at the X-axis including the number of reports and the percentage of total. On the y-axis the
distribution of the age-categories within each ATC class is presented, counting up to 100%. Within the bars
the proportion of this ATC class within the total number of reported drugs within the specified age-category is
presented. Only those drugs with a recoded ATC code are included (N = 214,327).
doi:10.1371/journal.pone.0130399.g003
Table 3. Most frequently reported drugs.
27 days N (%) 28 days—23
months
N (%) 2–11 years N (%) 12–17 years N (%) Total N (%)
Zidovudine 310
(2.9%)
Palivizumab 1025
(3.3%)
Atomoxetine 4680
(4.9%)
Isotretinoin 2634
(3.4%)
Atomoxetine 6597
(3.1%)
Vitamines 229
(2.1%)
Paracetamol
combinations
905
(3.0%)
Methylphenidate 3557
(3.8%)
Atomoxetine 1897
(2.4%)
Methylphenidate 5224
(2.4%)
Ampicillin 170
(1.6%)
Paracetamol 746
(2.4%)
Montelukast 2067
(2.2%)
Methylphenidate 1637
(2.1%)
Paracetamol 3704
(1.7%)
Valproic
acid
160
(1.5%)
Ibuprofen 611
(2.0%)
Fluticasone 1705
(1.8%)
Paracetamol 1304
(1.7%)
Methotrexate 3192
(1.5%)
Dopamine 140
(1.3%)
Ranitidine 501
(1.6%)
Methotrexate 1669
(1.8%)
Methotrexate 1207
(1.5%)
Montelukast 3015
(1.4%)
Furosemide 138
(1.3%)
Mitoxantrone 372
(1.2%)
Paracetamol 1546
(1.6%)
Lamotrigine 1165
(1.5%)
Valproic acid 2887
(1.3%)
Gentamicin 137
(1.3%)
Furosemide 342
(1.1%)
Valproic acid 1524
(1.6%)
Drospirenone and
estrogen
1077
(1.4%)
Ibuprofen 2881
(1.3%)
Lamivudine 136
(1.3%)
Amoxicillin 328
(1.1%)
Somatropin 1392
(1.5%)
Inﬂiximab 1038
(1.3%)
Isotretinoin 2810
(1.3%)
Insulin 130
(1.2%)
Amoxicillin /
clavulanic acid
310
(1.0%)
Ibuprofen 1331
(1.4%)
Aripriprazole 1012
(1.3%)
Fluticasone 2590
(1.2%)
Nitric oxide 130
(1.2%)
Choline salicylate 309
(1.0%)
Salbutamol 1260
(1.3%)
Valproic acid 940
(1.2%)
Lamotrigine 2483
(1.2%)
doi:10.1371/journal.pone.0130399.t003
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days of age to 13% at 12 to 17 years of age. Also reports of ‘nervous system disorders’ increased
with age from 7% at27 days of age to 12–13% at 2–17 years of age.
The number of reported drug-event pairs was calculated using the primary and secondary
suspected drugs only. The number of unique drug-event combinations was 548,640 overall and
within the age groups: 3,274 (27 days); 21,356 (28 days-23 months); 146,094 (2–11 years);
129,699 (12–17 years) (Table 5). Duration of drug use could be calculated for 63,311 drug rec-
ords (26.8%). The median duration of use was 10 days (range 0–6,209). The starting and event
date were equal in 28.4% of the records, 19.1% were reported after 1–7 days since starting.
Time to event was 8–30 days in 14.4% of the records, 31–182 days in 17.8% and>182 days
Fig 4. Proportions of reported events by system organ classes.Distribution of the number of reported
events over system organ classes (SOCs), stratified by age-categories. The reported SOCs are presented at
the X-axis including the number of reports and the percentage of total. On the y-axis the distribution of the
age-categories within each SOC is presented, counting up to 100%. Within the bars the proportion of this
SOC within the total number of reported events within the specified age-category is presented.
doi:10.1371/journal.pone.0130399.g004
Table 4. Most frequently reported events.
27 days N (%) 28 days—23
months
N (%) 2–11 years N (%) 12–17 years N (%) Total N (%)
Drug Exposure During
Pregnancy
1,350
(6.3%)
Pyrexia 1,068
(1.8%)
Vomiting 2,818
(1.6%)
Vomiting 1,878
(1.3%)
Vomiting 5,827
(1.5%)
Premature Baby 562
(2.6%)
Vomiting 1,046
(1.8%)
Pyrexia 2,425
(1.4%)
Headache 1,747
(1.2%)
Pyrexia 4,880
(1.2%)
Maternal Drugs
Affecting Foetus
484
(2.3%)
Convulsion 895
(1.5%)
Drug
Ineffective
2,394
(1.4%)
Nausea 1,641
(1.1%)
Convulsion 4,720
(1.2%)
Neonatal Disorders 381
(1.8%)
Accidental Drug
Intake By Child
789
(1.3%)
Convulsion 2,334
(1.3%)
Depression 1,581
(1.1%)
Drug
Ineffective
4,392
(1.1%)
Drug Withdrawal
Neonatal Syndrome
333
(1.6%)
Diarrhoea 645
(1.1%)
Abnormal
Behaviour
2,261
(1.3%)
Convulsion 1,399
(1.0%)
Headache 3,531
(0.9%)
Caesarean Section 328
(1.5%)
Accidental
Exposure
622
(1.0%)
Aggression 1,755
(1.0%)
Drug
Ineffective
1,365
(1.0%)
Abnormal
Behaviour
3,264
(0.8%)
Maternal Exposure
During Pregnancy
158
(0.7%)
Drug Ineffective 548
(0.9%)
Headache 1,733
(1.0%)
Pyrexia 1,322
(0.9%)
Nausea 3,093
(0.8%)
Neonatal Respiratory
Distress Syndrome
140
(0.7%)
Somnolence 544
(0.9%)
Somnolence 1,392
(0.8%)
Suicidal
Ideation
1,140
(0.8%)
Somnolence 2,903
(0.7%)
Drug Exposure Via
Breast Milk
134
(0.6%)
Product Quality
Issue
541
(0.9%)
Nausea 1,330
(0.8%)
Overdose 1,118
(0.8%)
Overdose 2,713
(0.7%)
Patent Ductus
Arteriosus
122
(0.6%)
Overdose 540
(0.9%)
Product Quality
Issue
1,238
(0.7%)
Suicide
Attempt
1,113
(0.8%)
Aggression 2,710
(0.7%)
doi:10.1371/journal.pone.0130399.t004
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(defined as long-term use) in 20.2% of the records. The proportion of drugs being used long-
term increased with age: 7.8% (28 days-23 months); 22.0% (2–11 years) and 24.1% (12–17
years). Within drug groups (i.e. ATC I level) the main differences between long-term use and
short-term use concerned drugs belonging to ‘systemic hormonal preparations’ [10.1% of ADRs
due to long-term use vs. 2.9% of ADRs due to short-term use; ratio: 3.5 (95% CI: 1.8–6.1)] and
to ‘alimentary drugs’ [10.8% vs. 5.8%; 3.9 (2.1–6.8)]. On the contrary, the drug groups more
reported after their short-term than long-term use were ‘anti-infectives’ [18.0% for short-term
use vs. 7.1% for long-term use; ratio: 2.5 (1.6–3.9)], ‘musculoskeletal system drugs’ [4.4% vs.
1.6%; 2.8 (0.8–6.0)], and ‘sensory organ agents’ [4.5% vs. 2.2%; 2.0 (0.6–4.4)]. The most fre-
quently reported drugs after long-term use were ‘somatropin’ (N = 955; 7.5%), ‘atomoxetine’
(N = 507; 4.0%), and ‘methylphenidate’ (N = 462; 3.6%).
In terms of SOCs, ‘neoplasms benign and malignant’ [2.1% vs. 0.5%; ratio: 4.2 (0.7–13.1)],
‘infections and infestations’ [7.0% vs. 4.8%; 1.5 (0.6–2.9)] and ‘musculoskeletal, connective tissue
and bone disorders’ [3.8% vs. 2.3%; 1.7 (0.6–4.2)] were more often reported after long-term use,
but the differences were no significant. The most frequently reported events after long-term
use were ‘vomiting’ (N = 415; 1.2%), ‘convulsion’ (N = 412; 1.2%), and ‘pyrexia’ (N = 389;
1.2%). For 47,301 drug records (20.0%) the time between ceasing of therapy and occurrence of
the event was known. The event occurred prior to stopping of the drug in 42.1% of the records,
on the day of stopping of the drug in 31.5% and after stopping of therapy in 26.4%. Of the
drugs occurring after stopping therapy, 45.2% occurred within 1–7 days, 27.0% occurred
within 8–30 days, 11.3% within 31–90 days, 5.4% within 91–182 days, 5.1% within 183–365
days and 6.0% after 365 days. When comparing the drug classes reported>90 days of ceasing
of therapy with those drug classes reported during drug use, the largest differences, with higher
proportion for delayed effects, were present for ‘antineoplastic and immunomodulating agents’
[26.6% vs. 9.9%; ratio: 2.7 (1.8–3.9)], and ‘dermatologicals’ [10.8% vs. 5.1%; 2.1 (1.1–3.7)],
while no significant differences were for the other drug groups. The most frequently reported
drugs after delayed use (>3 months) were ‘isotretinoin’ (N = 184; 8.8%), ‘palivizumab’ (N = 95;
4.5%), and ‘infliximab’ (N = 75; 3.6%). ‘Neoplasms benign and malignant’ [2.9% vs. 0.6%; ratio:
4.8 (1.3–13.6)], ‘gastrointestinal disorders’ [14.8% vs. 9.8%; 1.5 (0.9–2.5)], and ‘infections and
infestations’ [7.5% vs. 4.6%; 1.6 (0.8–3.3)] were the most frequently SOCs reported 3 months
after stopping. The most frequently reported delayed events were ‘Crohn’s disease’ (N = 106;
1.7%), ‘inflammatory bowel disease’ (N = 98; 1.6%), and ‘depression’ (N = 89; 1.4%).
Discussion
We explored the characteristics of the reports in children and adolescents in the US FAERS
database, including number and type of ICSRs, their outcome and the most frequently impli-
cated drugs and events. The largest proportion of ICSRs was reported for boys until the age of
11 after which it reversed to girls. These findings, in line with previous researches on other
spontaneous reporting systems [14, 25], can be explained by several factors. On one hand,
some childhood diseases, i.e. asthma [26], certain infections [27], ADHD [28], requiring a
treatment with medications commonly implicated in ICSRs, occur more frequently among
younger boys than younger girls; afterwards, the incidence changes during the adolescence,
mainly for asthma and urinary tract infections, with higher occurrence among girls than boys.
On the other hand, younger boys and older girls might be physiologically vulnerable to adverse
events. Irrespective of the gender, we found an overall increase of the absolute number of
reports with age increasing that could be attributed to a greater exposure to the medications in
adolescents [29].
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Pediatric adverse events reported to FAERS have been previously investigated by Johann-
Liang et al., with focus on potential change of the trend of spontaneous reporting following the
implementation of the Best Pharmaceuticals for Children Act (BPCA) in 2002 [15]. Then, they
investigated the differences in children and adults with regard to drug safety monitoring and
reporting. Conversely, we aimed to analyze the distribution of the adverse events reported in
children in terms of age-categories. We observed an expected variation between age-categories
in the type of reported drug and event, consistently with drug prescribing pattern in US. As
example, the increase of the proportion of ICSRs involving nervous system drugs after 2 years
of age is explained by the highest rates of prescriptions of ADHD therapies (i.e. ‘methylpheni-
date’) in adolescents [30]. As a consequence, we might explain the observed increase of adverse
events like as nervous system and psychiatric disorders in adolescents.
The pediatric ICSRs coming from US were previously described by Star et al., through the
analysis of VigiBase [14]. Although US reports make up the largest proportion of the ICSRs
both within FAERS (58%) and within VigiBase (39%), striking differences between the datasets
are present. First, the type of reporters differed. While more than half of the ICSRs of VigiBase
were reported by physicians, only a third of the FAERS ICSRs were reported by physicians.
The most notable difference was for consumer reports; 24.9% of the FAERS reports versus
4.3% within VigiBase. This difference might be due to different time-periods; consumer report-
ing is increasing in latest years [31]. Second, only a small proportion of the FAERS ICSRs con-
cerned reporting by non-manufacturers. The majority was either reported as part of expedited
reporting (65%) or as part of periodic reporting. Earlier it was shown that the US reports within
VigiBase are mainly reported by manufacturers, while these form only a small proportion of
the reports from the other continents [7]. Third, the reported drug groups and events differed.
VigiBase reports more often concerned ‘anti-infectives’ and ‘dermatological drugs’, while within
FAERS ‘neurological drugs’ and ‘antineoplastic drugs’ were most frequently reported. This also
reflects utilization differences between the US and Europe, with high rates of prescriptions of
‘methylphenidate’ in US adolescents in recent years [30]. Choosing an appropriate time-period
to study these kind of drugs is essential since the utilization of ‘neurological drugs’ and espe-
cially for the treatment of ADHD has changed tremendously since the start of VigiBase in 1968
[30, 32].
To our knowledge, our study is the first research focusing on long term use and on delayed
adverse events in children. Describing of ICSRs reported after long-term drug use was a topic
of special interest. Long-term drug use and long-term adverse events are of importance during
childhood because of possible effects on growth and development. However, they are difficult
to detect in clinical studies. These studies often lack sufficient time of follow-up and adverse
events occurring long after initiating therapy are not easily recognised. Especially for drugs
being used chronically or for adverse events that require a long duration of exposure (such as
cancer, and certain types of infections), studies investigating long-term safety should be per-
formed. The reported types of drugs before and after 6 months of use differed significantly.
‘Systemic hormonal preparations’, ‘alimentary drugs’ and ‘antineoplastic/immunomodulating
agents’ were prominently reported after long-term treatment (>6 months), while ‘anti-infective
drugs’, ‘musculoskeletal system drugs’ and ‘sensory organ drugs’ were reported mostly with short
term use. These findings are in line with drugs known to be used short-term or are known to
be used for long periods of time [29]. New onset neoplasms are an important concern and were
more often reported after long-term drug use. It is not possible to infer any causal association
based on spontaneous reporting data. However, the distribution of the drug classes and events
reported after long-term drug use are in line with what is expected and therefore a complete
dataset of pediatric ICSRs might be a suitable additional source to generate signals on delayed
events and new onset chronic events.
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The GRiP network aims to create an infrastructure promoting global drug safety surveil-
lance in children. Signal detection analysis within spontaneous reporting databases is an
important tool for pharmacovigilance, which may be followed by signal prioritization and eval-
uation analysis [24]. Information about the availability and the characteristics of data collected
in systems as AERS is a key step in the development of pediatric specific methodology for post-
marketing drug safety studies. Indeed, signal detection is influenced by the type of ICSRs, as
previously demonstrated [33], as well as the distribution of other factors including the type of
reporter and year of reporting [25]. For this reason, understanding the differences in the distri-
bution of reported drugs and events within database and between different databases, like
FAERS and VigiBase, gives insight on which factors might be of impact on the results but also
helps choosing the right database for a specific research hypothesis.
The use of spontaneous reporting data has many well-known limitations [34]. Since the
publically available datasets often do not include all variables there are analytic limitations and
since case-narratives are lacking it is difficult to draw inferences on causality. For example, the
non-availability of case-narratives implies a loss of potentially important information not oth-
erwise coded in the ICSR. Another well-known, limitation is the volume of duplicates [35].
Duplicate reports are present in all spontaneous reporting databases [36]. The identification
and elimination of duplicates from analyses is advantageous for using the data and is important
for a correct interpretation of the data, however, so far, few easy to use duplicate-detection
methods are currently available and enhanced methods of duplicate detection are being devel-
oped [35]. For this study, we dealt with the issue of duplicate reports by only including unique
ICSRs. However it is inevitable that duplicate reports are still present within the used database.
Conclusions
Knowledge on the distribution of the drug classes and events within FAERS is a key first step in
developing pediatric specific methods for drug safety surveillance. Because of several differ-
ences in terms of drugs and events among age-categories, drug safety signal detection analysis
in children need to be stratified by age groups.
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